A citation-based method for searching scientific literature


List of co-cited articles
45 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
801
57

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Gerard J Marek, Berthold Behl, Anton Y Bespalov, Gerhard Gross, Younglim Lee, Hans Schoemaker. Mol Pharmacol 2010
122
42

NMDA receptor hypofunction model of schizophrenia.
J W Olney, J W Newcomer, N B Farber. J Psychiatr Res 1999
718
42

The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801.
Karel Vales, Jan Svoboda, Kristina Benkovicova, Vera Bubenikova-Valesova, Ales Stuchlik. Eur J Pharmacol 2010
34
42


Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists.
Elena H Chartoff, Carrie L Heusner, Richard D Palmiter. Neuropsychopharmacology 2005
82
28




Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.
C Andersson, M Chakos, R Mailman, J Lieberman. Psychiatr Clin North Am 1998
18
28

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
247
28

Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
Chantal Schlumberger, Małgorzata Pietraszek, Andreas Gravius, Kai-Uwe Klein, Sergio Greco, Lorenzo Morè, Wojciech Danysz. Eur J Pharmacol 2009
41
28

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
28

Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine.
Daniela Polese, Antonella Amato de Serpis, Alberto Ambesi-Impiombato, Giovanni Muscettola, Andrea de Bartolomeis. Neuropsychopharmacology 2002
59
28

Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals.
E Luccini, V Musante, E Neri, M Brambilla Bas, P Severi, M Raiteri, A Pittaluga. Br J Pharmacol 2007
37
28


Dopamine hypothesis of schizophrenia: making sense of it all.
Mitsuru Toda, Anissa Abi-Dargham. Curr Psychiatry Rep 2007
124
28

Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.
C Chiamulera, M P Epping-Jordan, A Zocchi, C Marcon, C Cottiny, S Tacconi, M Corsi, F Orzi, F Conquet. Nat Neurosci 2001
435
28


mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
M Pietraszek, A Gravius, D Schäfer, T Weil, D Trifanova, W Danysz. Neuropharmacology 2005
74
28

Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator.
Francois Gastambide, Marie-Caroline Cotel, Gary Gilmour, Michael J O'Neill, Trevor W Robbins, Mark D Tricklebank. Neuropsychopharmacology 2012
75
28


Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release.
Houman Homayoun, Mark R Stefani, Barbara W Adams, Gilles D Tamagan, Bita Moghaddam. Neuropsychopharmacology 2004
206
28

Comparing protein abundance and mRNA expression levels on a genomic scale.
Dov Greenbaum, Christopher Colangelo, Kenneth Williams, Mark Gerstein. Genome Biol 2003
28


NMDA-induced phosphorylation and regulation of mGluR5.
Sudar Alagarsamy, Susan T Rouse, Candace Junge, G W Hubert, David Gutman, Yoland Smith, P Jeffrey Conn. Pharmacol Biochem Behav 2002
49
28


In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
Gary Gilmour, Lisa M Broad, Keith A Wafford, Thomas Britton, Ellen M Colvin, Adam Fivush, Francois Gastambide, Brian Getman, Beverly A Heinz, Andrew P McCarthy,[...]. Neuropharmacology 2013
44
28



Glutamatergic mechanisms in schizophrenia.
Guochuan Tsai, Joseph T Coyle. Annu Rev Pharmacol Toxicol 2002
441
28

Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP.
Y M Lu, Z Jia, C Janus, J T Henderson, R Gerlai, J M Wojtowicz, J C Roder. J Neurosci 1997
498
28



Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
512
28



Effects of microinjections of apomorphine and haloperidol into the inferior colliculus on the latent inhibition of the conditioned emotional response.
Liana L Melo, Ellen C H M Pereira, Cássia H Pagini, Norberto C Coimbra, Marcus L Brandão, Elenice A M Ferrari. Exp Neurol 2009
6
33


Animal models of schizophrenia.
C A Jones, D J G Watson, K C F Fone. Br J Pharmacol 2011
461
28

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
Daniela Alberati, Jean-Luc Moreau, Judith Lengyel, Nicole Hauser, Roland Mory, Edilio Borroni, Emmanuel Pinard, Frederic Knoflach, Götz Schlotterbeck, Dominik Hainzl,[...]. Neuropharmacology 2012
101
28

Animal behavior models of the mechanisms underlying antipsychotic atypicality.
Mark A Geyer, Bart Ellenbroek. Prog Neuropsychopharmacol Biol Psychiatry 2003
195
28



Neural mechanisms of addiction: the role of reward-related learning and memory.
Steven E Hyman, Robert C Malenka, Eric J Nestler. Annu Rev Neurosci 2006
28

GABAergic interneuron origin of schizophrenia pathophysiology.
Kazu Nakazawa, Veronika Zsiros, Zhihong Jiang, Kazuhito Nakao, Stefan Kolata, Shuqin Zhang, Juan E Belforte. Neuropharmacology 2012
319
14

The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.
Chris S Busse, Jesse Brodkin, David Tattersall, Jeffery J Anderson, Noelle Warren, Lida Tehrani, Linda J Bristow, Mark A Varney, Nicholas D P Cosford. Neuropsychopharmacology 2004
135
14

The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia.
R S Devon, S Anderson, P W Teague, W J Muir, V Murray, A J Pelosi, D H Blackwood, D J Porteous. Mol Psychiatry 2001
69
14

Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.
Jason M Uslaner, Sophie Parmentier-Batteur, Rosemarie B Flick, Nathaniel O Surles, June S H Lam, Caitlyn H McNaughton, Marlene A Jacobson, Pete H Hutson. Neuropharmacology 2009
122
14



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.